|
Title
|
|
|
|
Phase
|
|
|
|
Protocol
IDs
|
|
|
|
Toxicity/Benefit Ratio Optimization of Chemotherapy in Colorectal Cancer (CRC) Patients by Determination of Individual Genotypic Determinants
|
|
|
|
Phase IV
|
|
|
|
COLOGEN
NCT00138060
|
|
|
Relationship Between Platinum Levels in the Blood and Neurotoxicity in Patients Who Are Receiving Oxaliplatin for Gastrointestinal Cancer
|
|
|
|
Phase IV
|
|
|
|
GERCOR-TAUROX
SANOFI-GERCOR-TAUROX, EU-20573, NCT00274885
|
|
|
Preoperative Assessment for Synchronous Carcinoma or Polyps With MR Colonography
|
|
|
|
Phase IV
|
|
|
|
KA05030-MA
KA05030, NCT00300547
|
|
|
Elaboration of a Model for Predicting Efficacy of Monoclonal Antibodies (Cetuximab and Bevacizumab) in Patients With Colorectal Cancer and Liver Metastases
|
|
|
|
Phase IV
|
|
|
|
2005-401
NCT00327093
|
|
|
Concentration of Ertapenem in Colorectal Tissue
|
|
|
|
Phase IV
|
|
|
|
01-07
NCT00535652
|
|
|
Study of Biomarkers in Patients Undergoing Chemotherapy for Metastatic Colorectal Cancer
|
|
|
|
Phase IV
|
|
|
|
CHUL-BIO-COLON
RECF0356, INCA-RECF0356, NCT00559676
|
|
|
OBELIX Study: A Study of Avastin (Bevacizumab) in Combination With XELOX in Patients With Metastatic Cancer of the Colon or Rectum.
|
|
|
|
Phase IV
|
|
|
|
ML21380
NCT00577031
|
|
|
Pharmacokinetic Study of Capecitabine in Elderly Cancer Patient (= 75 Years)
|
|
|
|
Phase IV
|
|
|
|
I07028
N° EudraCT : 2008-001195-7, NCT00812864
|
|
|
Study to Evaluate the Clinical Benefit Response in Cancer Patients With Advanced Disease With AMT2003 Versus Placebo
|
|
|
|
Phase III, Phase II
|
|
|
|
AMT/P2CA/001
LC003AURON2005, NCT00332280
|
|
|
First Line Metastatic Colorectal Cancer Therapy in Combination With FOLFOX
|
|
|
|
Phase III, Phase II
|
|
|
|
D8480C00013
Eudract Number 2005-003440-66, NCT00384176
|
|